Cataloguenumber
PKA-099
Synonyms
KDRD1-7,sKDRD1-7,Kinaseinsertdomainreceptor,Protein-tyrosinekinasereceptorFlk-1,CD309,typeIIIreceptortyrosinekinase,FLK1,VEGFR-2.
Introduction
Endothelialcellsexpressthreedifferentvascularendothelialgrowthfactor(VEGF)receptors,belongingtothefamilyofreceptortyrosinekinases(RTKs).TheyarenamedVEGFR-1(Flt-1),VEGFR-2(KDR/Flk-1),VEGFR-3(Flt-4).Theirexpressionisalmostexclusivelyrestrictedtoendothelialcells,butVEGFR-1canalsobefoundonmonocytes.AllVEGF-receptorshavesevenimmunoglobulin-likeextracellulardomains,asingletransmembraneregionandanintracellularsplittyrosinekinasedomain.VEGFR-2hasaloweraffinityforVEGFthantheFlt-1receptor,butahighersignalingactivity.MitogenicactivityinendothelialcellsismainlymediatedbyVEGFR-2leADIngtotheirproliferation.
Differentialsplicingoftheflt-1geneleadstotheformationofasecreted,solublevariantofVEGFR-1(sVEGFR-1).Nonaturallyoccuring,secretedformsofVEGFR-2havesofarbeenreported.ThebindingofVEGF165toVEGFR-2isdependentonheparin.
Description
VEGFR2HumanRecombinantproducedinSf9Baculoviruscellsisasingle,glycosylatedpolypeptidechaincontaining987aminoacids(20-764a.a)andhavingamolecularmassof110.5kDa(MolecularsizeonSDS-PAGEwillappearatapproximately100-150kDa).VEGFR2isfusedtoa239aminoacidshIgG-His-tagatC-terminus&purifiedbyproprietarychromatographictechniques.
Source
Sf9,Baculoviruscells.
PhysicalAppearance
Formulation
VEGFR2solution(0.5mg/ml)containsPhosphateBufferedSaline(pH7.4)and10%glycerol.
StABIlity
Storeat4°Cifentirevialwillbeusedwithin2-4weeks.Store,frozenat-20°Cforlongerperiodsoftime.
Forlongtermstorageitisrecommendedtoaddacarrierprotein(0.1%HSAorBSA).
Avoidmultiplefreeze-thawcycles.
Purity
Greaterthan90%asdeterminedbySDS-PAGE.
Aminoacidsequence
ADPASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLELEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKHHHHHH.
